These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33045437)

  • 21. Site of infection rather than vancomycin MIC predicts vancomycin treatment failure in methicillin-resistant Staphylococcus aureus bacteraemia.
    Walraven CJ; North MS; Marr-Lyon L; Deming P; Sakoulas G; Mercier RC
    J Antimicrob Chemother; 2011 Oct; 66(10):2386-92. PubMed ID: 21775337
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of Vancomycin and β-Lactam Therapy for Methicillin-Resistant Staphylococcus aureus Bacteremia: A Pilot Multicenter Randomized Controlled Trial.
    Davis JS; Sud A; O'Sullivan MVN; Robinson JO; Ferguson PE; Foo H; van Hal SJ; Ralph AP; Howden BP; Binks PM; Kirby A; Tong SYC; ; ; Tong S; Davis J; Binks P; Majumdar S; Ralph A; Baird R; Gordon C; Jeremiah C; Leung G; Brischetto A; Crowe A; Dakh F; Whykes K; Kirkwood M; Sud A; Menon M; Somerville L; Subedi S; Owen S; O'Sullivan M; Liu E; Zhou F; Robinson O; Coombs G; Ferguson P; Ralph A; Liu E; Pollet S; Van Hal S; Foo H; Van Hal S; Davis R
    Clin Infect Dis; 2016 Jan; 62(2):173-180. PubMed ID: 26349552
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ceftaroline fosamil monotherapy for methicillin-resistant Staphylococcus aureus bacteremia: a comparative clinical outcomes study.
    Arshad S; Huang V; Hartman P; Perri MB; Moreno D; Zervos MJ
    Int J Infect Dis; 2017 Apr; 57():27-31. PubMed ID: 28131729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study.
    Moore CL; Osaki-Kiyan P; Haque NZ; Perri MB; Donabedian S; Zervos MJ
    Clin Infect Dis; 2012 Jan; 54(1):51-8. PubMed ID: 22109947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment strategies for persistent methicillin-resistant Staphylococcus aureus bacteraemia.
    Lewis PO; Heil EL; Covert KL; Cluck DB
    J Clin Pharm Ther; 2018 Oct; 43(5):614-625. PubMed ID: 30003555
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Outcomes of Vancomycin plus a β-Lactam versus Vancomycin Only for Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Truong J; Veillette JJ; Forland SC
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29133561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High vancomycin minimum inhibitory concentration is a predictor of mortality in meticillin-resistant Staphylococcus aureus bacteraemia.
    Wi YM; Kim JM; Joo EJ; Ha YE; Kang CI; Ko KS; Chung DR; Song JH; Peck KR
    Int J Antimicrob Agents; 2012 Aug; 40(2):108-13. PubMed ID: 22633565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictors of persistent methicillin-resistant Staphylococcus aureus bacteraemia in patients treated with vancomycin.
    Yoon YK; Kim JY; Park DW; Sohn JW; Kim MJ
    J Antimicrob Chemother; 2010 May; 65(5):1015-8. PubMed ID: 20200036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk factors for mortality in patients with persistent methicillin-resistant Staphylococcus aureus bacteraemia in a tertiary care hospital in Taiwan.
    Lin SH; Liao WH; Lai CC; Liao CH; Tan CK; Wang CY; Huang YT; Hsueh PR
    J Antimicrob Chemother; 2010 Aug; 65(8):1792-8. PubMed ID: 20511366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Focusing the Lens on the CAMERA Concepts: Early Combination β-Lactam and Vancomycin Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia.
    Wilsey HA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2020 Jun; 64(7):. PubMed ID: 32366709
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation.
    Moise PA; Culshaw DL; Wong-Beringer A; Bensman J; Lamp KC; Smith WJ; Bauer K; Goff DA; Adamson R; Leuthner K; Virata MD; McKinnell JA; Chaudhry SB; Eskandarian R; Lodise T; Reyes K; Zervos MJ
    Clin Ther; 2016 Jan; 38(1):16-30. PubMed ID: 26585355
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of linezolid in methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infection (cSSTI): a meta-analysis.
    Bounthavong M; Hsu DI
    Curr Med Res Opin; 2010 Feb; 26(2):407-21. PubMed ID: 20001574
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia.
    Song KH; Kim HB; Kim HS; Lee MJ; Jung Y; Kim G; Hwang JH; Kim NH; Kim M; Kim CJ; Choe PG; Chung JY; Park WB; Kim ES; Park KU; Kim NJ; Kim EC; Oh MD
    Int J Antimicrob Agents; 2015 Dec; 46(6):689-95. PubMed ID: 26555059
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
    Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Empiric guideline-recommended weight-based vancomycin dosing and nephrotoxicity rates in patients with methicillin-resistant Staphylococcus aureus bacteremia: a retrospective cohort study.
    Hall RG; Hazlewood KA; Brouse SD; Giuliano CA; Haase KK; Frei CR; Forcade NA; Bell T; Bedimo RJ; Alvarez CA
    BMC Pharmacol Toxicol; 2013 Feb; 14():12. PubMed ID: 23402420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The empirical combination of vancomycin and a β-lactam for Staphylococcal bacteremia.
    McConeghy KW; Bleasdale SC; Rodvold KA
    Clin Infect Dis; 2013 Dec; 57(12):1760-5. PubMed ID: 23985343
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized phase 2B trial of vancomycin versus daptomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteremia due to isolates with high vancomycin minimum inhibitory concentrations - results of a prematurely terminated study.
    Kalimuddin S; Chan YFZ; Phillips R; Ong SP; Archuleta S; Lye DC; Tan TT; Low JGH
    Trials; 2018 Jun; 19(1):305. PubMed ID: 29859132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of source of infection and vancomycin AUC0-24/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Ghosh N; Chavada R; Maley M; van Hal SJ
    Clin Microbiol Infect; 2014 Dec; 20(12):O1098-105. PubMed ID: 24890030
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies.
    Shorr AF; Kunkel MJ; Kollef M
    J Antimicrob Chemother; 2005 Nov; 56(5):923-9. PubMed ID: 16195255
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nephrotoxicity of vancomycin in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
    Shen WC; Chiang YC; Chen HY; Chen TH; Yu FL; Tang CH; Sue YM
    Nephrology (Carlton); 2011 Nov; 16(8):697-703. PubMed ID: 21707841
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.